CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech)

N/A

Report date: 2024/07/05 11:08:40

Base Information

Drug NameCAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech)
Drug Alias NameCD123/CD33 CART cell therapy(Essen Biotech)Anti CD33/CD123 chimeric antigen receptor T cell therapy(Essen Biotech)BAH244BAH-244
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsMyeloid cell surface antigen CD33 modulators
TargetsInterleukin-3 receptor subunit alphaMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A